Obesity-related complications: Few biochemical phenomena with reference to tumorigenesis

Malaysian Journal of Pathology

Volumn 35, Issue 1, 2013, Pages 1-15

  Iskander, Kirolos ^a   Farhour, Reza ^a   Ficek, Monica ^a   Ray, Amitabha ^a  

^a SAINT JAMES SCHOOL OF MEDICINE   (Anguilla)

Author keywords

Adipokines; Cancer; Cholesterol; Clinical biochemistry; Insulin resistance; Obesity; Oestrogen

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; CHOLESTEROL; CYTOKINE; ENDOCRINE DISRUPTOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERLEUKIN 6; LEPTIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RESISTIN; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN C; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

CARCINOGENESIS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CLINICAL ASSESSMENT; CYTOKINE PRODUCTION; EARLY DIAGNOSIS; HUMAN; IN VIVO STUDY; INSULIN RESISTANCE; MOUSE; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOGENESIS; PROGNOSIS; RAT; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; NEOPLASMS; OBESITY;

EID: 84879594882     PISSN: 01268635     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (137)

1. von Ruesten A, Steffen A, Floegel A, et al. Trend in obesity prevalence in European adult cohort populations during follow-up since 1996 and their predictions to 2015. PLoS One. 2011; 6(11): e27455.
2. Popkin BM, Adair LS, Ng SW. Global nutrition transition and the pandemic of obesity in developing countries. Nutr Rev. 2012; 70(1): 3-21.
3. Hurt RT, Frazier TH, McClave SA, Kaplan LM. Obesity epidemic: overview, pathophysiology, and the intensive care unit conundrum. JPEN J Parenter Enteral Nutr. 2011; 35(5 Suppl): 4S-13S.
4. Henry FJ. Obesity prevention: the key to noncommunicable disease control. West Indian Med J. 2011; 60(4): 446-51.
5. Emanuela F, Grazia M, Marco de R, Maria Paola L, Giorgio F, Marco B. Infl ammation as a link between obesity and metabolic syndrome. J Nutr Metab. 2012; 2012: 476380.
6. Taube A, Schlich R, Sell H, Eckardt K, Eckel J. Infl ammation and metabolic dysfunction: links to cardiovascular diseases. Am J Physiol Heart Circ Physiol. 2012; 302(11): H2148-65.
7. Mayi TH, Daoudi M, Derudas B, et al. Human adipose tissue macrophages display activation of cancer-related pathways. J Biol Chem. 2012; 287(26): 21904-13.
8. Caspar-Bauguil S, Cousin B, Bour S, Casteilla L, Penicaud L, Carpéné C. Adipose tissue lymphocytes: types and roles. J Physiol Biochem. 2009; 65(4): 423-36.
9. O'Rourke RW, Kay T, Scholz MH, et al. Alterations in T-cell subset frequency in peripheral blood in obesity. Obes Surg. 2005; 15(10): 1463-8.
10. Nishimura S, Manabe I, Nagasaki M, et al. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue infl ammation in obesity. Nat Med. 2009; 15(8): 914-20.
11. Tanaka S, Isoda F, Ishihara Y, Kimura M, Yamakawa T. T lymphopaenia in relation to body mass index and TNF-alpha in human obesity: adequate weight reduction can be corrective. Clin Endocrinol (Oxf). 2001; 54(3): 347-54.
12. Moulin CM, Marguti I, Peron JP, Rizzo LV, Halpern A. Impact of adiposity on immunological parameters. Arq Bras Endocrinol Metabol. 2009; 53(2): 183-9.
13. de Sá VK, Carvalho L, Gomes A, et al. Role of the extracellular matrix in variations of invasive pathways in lung cancers. Braz J Med Biol Res. 2013; 46(1): 21-31.
14. Sounni NE, Noel A. Targeting the tumor microenvironment for cancer therapy. Clin Chem. 2013; 59(1): 85-93.
15. Wong GS, Rustgi AK. Matricellular proteins: priming the tumour microenvironment for cancer development and metastasis. Br J Cancer. 2013; 108(4): 755-61.
16. Mariman EC, Wang P. Adipocyte extracellular matrix composition, dynamics and role in obesity. Cell Mol Life Sci. 2010; 67(8): 1277-92.
17. Catalán V, Gómez-Ambrosi J, Rodríguez A, Frühbeck G. Role of extracellular matrix remodelling in adipose tissue pathophysiology: relevance in the development of obesity. Histol Histopathol. 2012; 27(12): 1515-28.
18. Nomiyama T, Perez-Tilve D, Ogawa D, et al. Osteopontin mediates obesity-induced adipose tissue macrophage infi ltration and insulin resistance in mice. J Clin Invest. 2007; 117(10): 2877-88.
19. Li Q, Hata A, Kosugi C, Kataoka N, Funaki M. The density of extracellular matrix proteins regulates infl ammation and insulin signaling in adipocytes. FEBS Lett. 2010; 584(19): 4145-50.
20. Hopps E, Caimi G. Matrix metalloproteinases in metabolic syndrome. Eur J Intern Med. 2012; 23(2): 99-104.
21. Kang L, Lantier L, Kennedy A, et al. Hyaluronan accumulates with high fat feeding and contributes to insulin resistance. Diabetes. 2013; 62(6): 1888-96
22. Hefetz-Sela S, Scherer PE. Adipocytes: impact on tumor growth and potential sites for therapeutic intervention. Pharmacol Ther. 2013; 138(2): 197-210.
23. Park SY, Kim JS, Seo YR, Sung MK. Effects of diet-induced obesity on colitis-associated colon tumor formation in A/J mice. Int J Obes (Lond). 2012; 36(2): 273-80.
24. Gravaghi C, Bo J, Laperle KM, et al. Obesity enhances gastrointestinal tumorigenesis in Apcmutant mice. Int J Obes (Lond). 2008; 32(11): 1716-9.
25. Iatropoulos MJ, Duan JD, Jeffrey AM, et al. Hepatocellular proliferation and hepatocarcinogen bioactivation in mice with diet-induced fatty liver and obesity. Exp Toxicol Pathol. 2013; 65(4): 451-6.
26. Soga M, Hashimoto S, Kishimoto Y, Hirasawa T, Makino S, Inagaki S. Insulin resistance, steatohepatitis, and hepatocellular carcinoma in a new congenic strain of Fatty Liver Shionogi (FLS) mice with the Lep(ob) gene. Exp Anim. 2010; 59(4): 407-19.
27. Zyromski NJ, Mathur A, Pitt HA, et al. Obesity potentiates the growth and dissemination of pancreatic cancer. Surgery. 2009; 146(2): 258-63.
28. White PB, True EM, Ziegler KM, et al. Insulin, leptin, and tumoral adipocytes promote murine pancreatic cancer growth. J Gastrointest Surg. 2010; 14(12): 1888-93.
29. Schneider MB, Matsuzaki H, Haorah J, et al. Prevention of pancreatic cancer induction in hamsters by metformin. Gastroenterology. 2001; 120(5): 1263-70.
30. Zhang Q, Shen Q, Celestino J, et al. Enhanced estrogen-induced proliferation in obese rat endometrium. Am J Obstet Gynecol. 2009; 200(2): 186. e1-8.
31. Yu W, Cline M, Maxwell LG, et al. Dietary vitamin D exposure prevents obesity-induced increase in endometrial cancer in Pten+/-mice. Cancer Prev Res (Phila). 2010; 3(10): 1246-58.
32. Yakar S, Nunez NP, Pennisi P, et al. Increased tumor growth in mice with diet-induced obesity: impact of ovarian hormones. Endocrinology. 2006; 147(12): 5826-34.
33. Mori A, Sakurai H, Choo MK, et al. Severe pulmonary metastasis in obese and diabetic mice. Int J Cancer. 2006; 119(12): 2760-7.
34. Katiyar SK, Meeran SM. Obesity increases the risk of UV radiation-induced oxidative stress and activation of MAPK and NF-kappaB signaling. Free Radic Biol Med. 2007; 42(2): 299-310.
35. Rao GN. Infl uence of diet on tumors of hormonal tissues. Prog Clin Biol Res. 1996; 394: 41-56.
36. Hakkak R, MacLeod S, Shaaf S, et al. Obesity increases the incidence of 7,12-dimethylbenz(a) anthracene-induced mammary tumors in an ovariectomized Zucker rat model. Int J Oncol. 2007; 30(3): 557-63.
37. Nunez NP, Perkins SN, Smith NC, et al. Obesity accelerates mouse mammary tumor growth in the absence of ovarian hormones. Nutr Cancer. 2008; 60(4): 534-41.
38. Nkhata KJ, Ray A, Dogan S, Grande JP, Cleary MP. Mammary tumor development from T47-D human breast cancer cells in obese ovariectomized mice with and without estradiol supplements. Breast Cancer Res Treat. 2009; 114(1): 71-83.
39. Sinicrope FA, Dannenberg AJ. Obesity and breast cancer prognosis: weight of the evidence. J Clin Oncol. 2011; 29(1): 4-7.
40. Hakkak R, Holley AW, Macleod SL, et al. Obesity promotes 7,12-dimethylbenz(a)anthracene-induced mammary tumor development in female zucker rats. Breast Cancer Res. 2005; 7(5): R627-33.
41. Gordon RR, Hunter KW, La Merrill M, Sørensen P, Threadgill DW, Pomp D. Genotype X diet interactions in mice predisposed to mammary cancer: II. Tumors and metastasis. Mamm Genome. 2008; 19(3): 179-89.
42. Cleary MP, Grande JP, Maihle NJ. Effect of high fat diet on body weight and mammary tumor latency in MMTV-TGF-alpha mice. Int J Obes Relat Metab Disord. 2004; 28(8): 956-62.
43. Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan MP, Sherman ME. Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomarkers Prev. 2004; 13(10): 1558-68.
44. Khalid S, Hwang D, Babichev Y, et al. Evidence for a tumor promoting effect of high-fat diet independent of insulin resistance in HER2/Neu mammary carcinogenesis. Breast Cancer Res Treat. 2010; 122(3): 647-59.
45. Bassett JK, Severi G, Baglietto L, et al. Weight change and prostate cancer incidence and mortality. Int J Cancer. 2012; 131(7): 1711-9.
46. Blando J, Moore T, Hursting S, et al. Dietary energy balance modulates prostate cancer progression in Hi-Myc mice. Cancer Prev Res (Phila). 2011; 4(12): 2002-14.
47. Llaverias G, Danilo C, Wang Y, et al. A Westerntype diet accelerates tumor progression in an autochthonous mouse model of prostate cancer. Am J Pathol. 2010; 177(6): 3180-91.
48. Chitra U, Reddy NK, Balakrishna N. Role of lifestyle variables on the lipid profi le of selected South Indian subjects. Indian Heart J. 2012; 64(1): 28-34.
49. Wahab KW, Sani MU, Yusuf BO, Gbadamosi M, Gbadamosi A, Yandutse MI. Prevalence and determinants of obesity-a cross-sectional study of an adult Northern Nigerian population. Int Arch Med. 2011; 4(1): 10.
50. Saely CH, Risch L, Frey F, et al. Body mass index, blood pressure, and serum cholesterol in young Swiss men: an analysis on 56784 army conscripts. Swiss Med Wkly. 2009; 139(35-36): 518-24.
51. Yu BL, Zhao SP, Hu JR. Cholesterol imbalance in adipocytes: a possible mechanism of adipocytes dysfunction in obesity. Obes Rev. 2010; 11(8): 560-7.
52. Ding EL, Hu FB. Cancer and cholesterol: understanding the V-shaped association in patients with diabetes. CMAJ. 2008; 179(5): 403-4.
53. Martin BJ, van Golen KL. A comparison of cholesterol uptake and storage in infl ammatory and noninfl ammatory breast cancer cells. Int J Breast Cancer. 2012; 2012: 412581.
54. Krycer JR, Brown AJ. Cholesterol accumulation in prostate cancer: a classic observation from a modern perspective. Biochim Biophys Acta. 2013; 1835(2): 219-29.
55. Platz EA, Till C, Goodman PJ, et al. Men with low serum cholesterol have a lower risk of highgrade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev. 2009; 18(11): 2807-13.
56. Mondul AM, Clipp SL, Helzlsouer KJ, Platz EA. Association between plasma total cholesterol concentration and incident prostate cancer in the CLUE II cohort. Cancer Causes Control. 2010; 21(1): 61-8.
57. Shafique K, McLoone P, Qureshi K, Leung H, Hart C, Morrison DS. Cholesterol and the risk of grade-specifi c prostate cancer incidence: evidence from two large prospective cohort studies with up to 37 years' follow up. BMC Cancer. 2012; 12: 25.
58. Solomon KR, Freeman MR. The complex interplay between cholesterol and prostate malignancy. Urol Clin North Am. 2011; 38(3): 243-59.
59. Di Vizio D, Solomon KR, Freeman MR. Cholesterol and cholesterol-rich membranes in prostate cancer: an update. Tumori. 2008; 94(5): 633-9.
60. Staubach S, Hanisch FG. Lipid rafts: signaling and sorting platforms of cells and their roles in cancer. Expert Rev Proteomics. 2011; 8(2): 263-77.
61. Danilo C, Frank PG. Cholesterol and breast cancer development. Curr Opin Pharmacol. 2012; 12(6): 677-82.
62. Badid N, Ahmed FZ, Merzouk H, et al. Oxidant/ antioxidant status, lipids and hormonal profi le in overweight women with breast cancer. Pathol Oncol Res. 2010; 16(2): 159-67.
63. Naik SLD, Hedau S, Bahadur AK, Saha R, Kaur S, Ray A. Sex hormone binding globulin in breast cancer. Indian J Clin Biochem. 2008; 23(3): 250-4.
64. Abu-Bedair FA, El-Gamal BA, Ibrahim NA, El-Aaser AA. Serum lipids and tissue DNA content in Egyptian female breast cancer patients. Jpn J Clin Oncol. 2003; 33(6): 278-82.
65. Mady EA. Association between estradiol, estrogen receptors, total lipids, triglycerides, and cholesterol in patients with benign and malignant breast tumors. J Steroid Biochem Mol Biol. 2000; 75(4-5): 323-8.
66. Bahl M, Ennis M, Tannock IF, et al. Serum lipids and outcome of early-stage breast cancer: results of a prospective cohort study. Breast Cancer Res Treat. 2005; 94(2): 135-44.
67. Emaus A, Veierød MB, Tretli S, et al. Metabolic profi le, physical activity, and mortality in breast cancer patients. Breast Cancer Res Treat. 2010; 121(3): 651-60.
68. Kreger BE, Anderson KM, Schatzkin A, Splansky GL. Serum cholesterol level, body mass index, and the risk of colon cancer. The Framingham Study. Cancer. 1992; 70(5): 1038-43.
69. Bayerdörffer E, Mannes GA, Richter WO, et al. Decreased high-density lipoprotein cholesterol and increased low-density cholesterol levels in patients with colorectal adenomas. Ann Intern Med. 1993; 118(7): 481-7.
70. Houghton J, Lardieri GG, Zauber NP, Kim KH, Cable G. Effect of cholesterol levels on villous histology in colonic adenomas. Dig Dis Sci. 2000; 45(5): 896-9.
71. Fiorenza AM, Branchi A, Sommariva D. Serum lipoprotein profi le in patients with cancer. A comparison with non-cancer subjects. Int J Clin Lab Res. 2000; 30(3): 141-5.
72. Notarnicola M, Altomare DF, Correale M, et al. Serum lipid profi le in colorectal cancer patients with and without synchronous distant metastases. Oncology. 2005; 68(4-6): 371-4.
73. Kitahara CM, Berrington de González A, Freedman ND, et al. Total cholesterol and cancer risk in a large prospective study in Korea. J Clin Oncol. 2011; 29(12): 1592-8.
74. Han Z, Slack RS, Li W, Papadopoulos V. Expression of peripheral benzodiazepine receptor (PBR) in human tumors: relationship to breast, colorectal, and prostate tumor progression. J Recept Signal Transduct Res. 2003; 23(2-3): 225-38.
75. Galiègue S, Casellas P, Kramar A, Tinel N, Simony-Lafontaine J. Immunohistochemical assessment of the peripheral benzodiazepine receptor in breast cancer and its relationship with survival. Clin Cancer Res. 2004; 10(6): 2058-64.
76. Königsrainer I, Vogel UF, Beckert S, et al. Increased translocator protein (TSPO) mRNA levels in colon but not in rectum carcinoma. Eur Surg Res. 2007; 39(6): 359-63.
77. Leung HW, Chan AL, Lo D, Leung JH, Chen HL. Common cancer risk and statins: a population-based case-control study in a Chinese population. Expert Opin Drug Saf. 2013; 12(1): 19-27.
78. Gazzerro P, Proto MC, Gangemi G, et al. Pharmacological actions of statins: a critical appraisal in the management of cancer. Pharmacol Rev. 2012; 64(1): 102-46.
79. Boudreau DM, Yu O, Johnson J. Statin use and cancer risk: a comprehensive review. Expert Opin Drug Saf. 2010; 9(4): 603-21.
80. Wuermli L, Joerger M, Henz S, et al. Hypertriglyceridemia as a possible risk factor for prostate cancer. Prostate Cancer Prostatic Dis. 2005; 8(4): 316-20.
81. Hayashi N, Matsushima M, Yamamoto T, Sasaki H, Takahashi H, Egawa S. The impact of hypertriglyceridemia on prostate cancer development in patients aged dd60 years. BJU Int. 2012; 109(4): 515-9.
82. Van Hemelrijck M, Garmo H, Holmberg L, et al. Prostate cancer risk in the Swedish AMORIS study: the interplay among triglycerides, total cholesterol, and glucose. Cancer. 2011; 117(10): 2086-95.
83. Hammarsten J, Högstedt B. Clinical, haemodynamic, anthropometric, metabolic and insulin profi le of men with high-stage and high-grade clinical prostate cancer. Blood Press. 2004; 13(1): 47-55.
84. Potischman N, McCulloch CE, Byers T, et al. Associations between breast cancer, plasma triglycerides, and cholesterol. Nutr Cancer. 1991; 15(3-4): 205-15.
85. Han C, Zhang HT, Du L, et al. Serum levels of leptin, insulin, and lipids in relation to breast cancer in China. Endocrine. 2005; 26(1): 19-24.
86. Agnoli C, Berrino F, Abagnato CA, et al. Metabolic syndrome and postmenopausal breast cancer in the ORDET cohort: a nested case-control study. Nutr Metab Cardiovasc Dis. 2010; 20(1): 41-8.
87. Inoue M, Noda M, Kurahashi N, et al. Impact of metabolic factors on subsequent cancer risk: results from a large-scale population-based cohort study in Japan. Eur J Cancer Prev. 2009; 18(3): 240-7.
88. Wulaningsih W, Garmo H, Holmberg L, et al. Serum lipids and the risk of gastrointestinal malignancies in the Swedish AMORIS study. J Cancer Epidemiol. 2012; 2012: 792034.
89. Bird CL, Ingles SA, Frankl HD, Lee ER, Longnecker MP, Haile RW. Serum lipids and adenomas of the left colon and rectum. Cancer Epidemiol Biomarkers Prev. 1996; 5(8): 607-12.
90. Otani T, Iwasaki M, Ikeda S, et al. Serum triglycerides and colorectal adenoma in a case-control study among cancer screening examinees (Japan). Cancer Causes Control. 2006; 17(10): 1245-52.
91. Kumar A, Klinge CM, Goldstein RE. Estradiolinduced proliferation of papillary and follicular thyroid cancer cells is mediated by estrogen receptors alpha and beta. Int J Oncol. 2010; 36(5): 1067-80.
92. Chakraborty S, Ganti AK, Marr A, Batra SK. Lung cancer in women: role of estrogens. Expert Rev Respir Med. 2010; 4(4): 509-18.
93. Tanaka Y, Sasaki M, Kaneuchi M, Fujimoto S, Dahiya R. Estrogen receptor alpha polymorphisms and renal cell carcinoma-a possible risk. Mol Cell Endocrinol. 2003; 202(1-2): 109-16.
94. Chung SH, Shin MK, Korach KS, Lambert PF. Requirement for stromal estrogen receptor alpha in cervical neoplasia. Horm Cancer. 2013; 4(1): 50-9.
95. Foster PA. Oestrogen and colorectal cancer: mechanisms and controversies. Int J Colorectal Dis. 2013; 28(6): 737-49.
96. Wolin KY, Carson K, Colditz GA. Obesity and cancer. Oncologist. 2010; 15(6): 556-65.
97. Bershtein LM. Interrelations of cancer of hormone dependent tissues and other non-infectious diseases: aging aspect. Adv Gerontol. 2009; 22(2): 269-81.
98. Osório-Costa F, Rocha GZ, Dias MM, Carvalheira JB. Epidemiological and molecular mechanisms aspects linking obesity and cancer. Arq Bras Endocrinol Metabol. 2009; 53(2): 213-26.
99. Cleary MP, Grossmann ME, Ray A. Effect of obesity on breast cancer development. Vet Pathol. 2010; 47(2): 202-13.
100. Sasano H, Miki Y, Nagasaki S, Suzuki T. In situ estrogen production and its regulation in human breast carcinoma: from endocrinology to intracrinology. Pathol Int. 2009; 59(11): 777-89.
101. Zhang X, Tworoger SS, Eliassen AH, Hankinson SE. Postmenopausal plasma sex hormone levels and breast cancer risk over 20 years of follow-up. Breast Cancer Res Treat. 2013; 137(3): 883-92.
102. Liedtke S, Schmidt ME, Vrieling A, et al. Postmenopausal sex hormones in relation to body fat distribution. Obesity (Silver Spring). 2012; 20(5): 1088-95.
103. Endogenous Hormones and Breast Cancer Collaborative Group, Key TJ, Appleby PN, et al. Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies. Br J Cancer. 2011; 105(5): 709-22.
104. Yager JD. Endogenous estrogens as carcinogens through metabolic activation. J Natl Cancer Inst Monogr. 2000; (27): 67-73.
105. Kaaks R. Nutrition, insulin, IGF-1 metabolism and cancer risk: a summary of epidemiological evidence. Novartis Found Symp. 2004; 262: 247-60.
106. Jee SH, Kim HJ, Lee J. Obesity, insulin resistance and cancer risk. Yonsei Med J. 2005; 46(4): 449-55.
107. Ray A, Ray G, Murthy NS. Cancer chemoprevention and lifestyle factors: an overview of epidemiology and biological mechanisms. In: Arora R, editor. Herbal medicine: a cancer chemopreventive and therapeutic perspective. New Delhi: Jaypee Bros; 2010. p. 122-42.
108. Pischon T, Nöthlings U, Boeing H. Obesity and cancer. Proc Nutr Soc. 2008; 67(2): 128-45.
109. Inoue M, Tsugane S. Insulin resistance and cancer: epidemiological evidence. Endocr Relat Cancer. 2012; 19(5): F1-8.
110. Arcidiacono B, Iiritano S, Nocera A, et al. Insulin resistance and cancer risk: an overview of the pathogenetic mechanisms. Exp Diabetes Res. 2012; 2012: 789174.
111. Yun SJ, Min BD, Kang HW, et al. Elevated insulin and insulin resistance are associated with the advanced pathological stage of prostate cancer in Korean population. J Korean Med Sci. 2012; 27(9): 1079-84.
112. Housa D, Housová J, Vernerová Z, Haluzík M. Adipocytokines and cancer. Physiol Res. 2006; 55(3): 233-44.
113. Ceschi M, Gutzwiller F, Moch H, Eichholzer M, Probst-Hensch NM. Epidemiology and pathophysiology of obesity as cause of cancer. Swiss Med Wkly. 2007; 137(3-4): 50-6.
114. Grossmann ME, Ray A, Nkhata KJ, et al. Obesity and breast cancer: status of leptin and adiponectin in pathological processes. Cancer Metastasis Rev. 2010; 29(4): 641-53.
115. Barb D, Pazaitou-Panayiotou K, Mantzoros CS. Adiponectin: a link between obesity and cancer. Expert Opin Investig Drugs. 2006; 15(8): 917-31.
116. Garaulet M, Hernández-Morante JJ, de Heredia FP, Tébar FJ. Adiponectin, the controversial hormone. Public Health Nutr. 2007; 10(10A): 1145-50.
117. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004; 89(6): 2548-56.
118. Irigaray P, Newby JA, Lacomme S, Belpomme D. Overweight/obesity and cancer genesis: more than a biological link. Biomed Pharmacother. 2007; 61(10): 665-78.
119. Diamanti-Kandarakis E, Bourguignon JP, Giudice LC, et al. Endocrine-disrupting chemicals: an Endocrine Society scientifi c statement. Endocr Rev. 2009; 30(4): 293-342.
120. Meeker JD. Exposure to environmental endocrine disrupting compounds and men's health. Maturitas. 2010; 66(3): 236-41.
121. Baillie-Hamilton PF. Chemical toxins: a hypothesis to explain the global obesity epidemic. J Altern Complement Med. 2002; 8(2): 185-92.
122. Newbold RR, Padilla-Banks E, Jefferson WN. Environmental estrogens and obesity. Mol Cell Endocrinol. 2009; 304(1-2): 84-9.
123. Grün F, Watanabe H, Zamanian Z, et al. Endocrinedisrupting organotin compounds are potent inducers of adipogenesis in vertebrates. Mol Endocrinol. 2006; 20(9): 2141-55.
124. Masuno H, Iwanami J, Kidani T, Sakayama K, Honda K. Bisphenol A accelerates terminal differentiation of 3T3-L1 cells into adipocytes through the phosphatidylinositol 3-kinase pathway. Toxicol Sci. 2005; 84(2): 319-27.
125. Ruzzin J, Petersen R, Meugnier E, et al. Persistent organic pollutant exposure leads to insulin resistance syndrome. Environ Health Perspect. 2010; 118(4): 465-71.
126. Carpenter DO. Environmental contaminants as risk factors for developing diabetes. Rev Environ Health. 2008; 23(1): 59-74.
127. Murthy NS, Mukherjee S, Ray G, Ray A. Dietary factors and cancer chemoprevention: an overview of obesity-related malignancies. J Postgrad Med. 2009; 55(1): 45-54.
128. Llaneza P, González C, Fernandez-Iñarrea J, et al. Soy isofl avones, diet and physical exercise modify serum cytokines in healthy obese postmenopausal women. Phytomedicine. 2011; 18(4): 245-50.
129. Bradford PG. Curcumin and obesity. Biofactors. 2013; 39(1): 78-87.
130. Chaturvedi P. Antidiabetic potentials of Momordica charantia: multiple mechanisms behind the effects. J Med Food. 2012; 15(2): 101-7.
131. Kalgaonkar S, Nishioka H, Gross HB, Fujii H, Keen CL, Hackman RM. Bioactivity of a fl avanol-rich lychee fruit extract in adipocytes and its effects on oxidant defense and indices of metabolic syndrome in animal models. Phytother Res. 2010; 24(8): 1223-8.
132. Narasimhan ML, Coca MA, Jin J, et al. Osmotin is a homolog of mammalian adiponectin and controls apoptosis in yeast through a homolog of mammalian adiponectin receptor. Mol Cell. 2005; 17(2): 171-80.
133. Kritchevsky D. Caloric restriction and experimental carcinogenesis. Hybrid Hybridomics. 2002; 21(2): 147-51.
134. Longo VD, Fontana L. Calorie restriction and cancer prevention: metabolic and molecular mechanisms. Trends Pharmacol Sci. 2010; 31(2): 89-98.
135. Hursting SD, Smith SM, Lashinger LM, Harvey AE, Perkins SN. Calories and carcinogenesis: lessons learned from 30 years of calorie restriction research. Carcinogenesis. 2010; 31(1): 83-9.
136. Yassine HN, Marchetti CM, Krishnan RK, Vrobel TR, Gonzalez F, Kirwan JP. Effects of exercise and caloric restriction on insulin resistance and cardiometabolic risk factors in older obese adults--a randomized clinical trial. J Gerontol A Biol Sci Med Sci. 2009; 64(1): 90-5.
137. Larson-Meyer DE, Redman L, Heilbronn LK, Martin CK, Ravussin E. Caloric restriction with or without exercise: the fi tness versus fatness debate. Med Sci Sports Exerc. 2010; 42(1): 152-9.